GLP1R and type 2 diabetes mellitus: Specifically, eight trials investigated the effects of GLP-1 RA on cardiovascular outcomes (cardiovascular mortality, non-fatal MI, and non-fatal stroke) in patients with T2D and high cardiovascular risk (Table 3) [1,2,3,4,5,6,7,8].